Psilocybin mushrooms stand ready for harvest in a humidified “fruiting chamber.” John Moore | Getty Images Thursday’s announcement that Eli Lilly will acquire AtaiBeckley, a clinical-stage maker of psychedelic drugs, for up to $3.8 billion indicates Big Pharma’s increasing embrace of a long-stigmatized class of medications as alternatives for treating an array of mental health…
A beautiful, but over weight Maine Coon Cat gets measured around the belly by a vet. Ryersonclark | E+ | Getty Images Felix is five years old, loves food, and refuses to lose weight. His owner, Amy in Dallas, has tried cutting back on meals, but with two cats in the house, “he just gobbles…
UnitedHealth Group on Thursday posted second-quarter earnings that blew past estimates and raised its full-year profit outlook, as the company better manages high medical costs and uses AI to help streamline operations. The largest private insurer in the U.S. said it expects 2026 adjusted earnings of $19.50 to $20 per share, up from a previous…
Michael Siluk | UCG | Universal Images Group | Getty Images Losing weight with GLP-1 drugs is only half the battle. Keeping it off long term has proved even harder. Factors such as side effects, high out-of-pocket costs, injection fatigue and stigma around obesity treatment drive troves of patients – some studies estimate roughly half…
AstraZeneca‘s failed late-stage trial for Wainua was never expected to have a major financial impact on the company. Most analysts estimate the trial miss wiped just 2-4% from their valuation models. Yet the shares lost roughly twice that in a single session, suggesting the market reaction reflected more than just the loss of one drug,…
Abivax‘s latest funding round allows the biotech to move toward a U.S. launch of its bowel disease drug without backing from Big Pharma, CEO Marc de Garidel told CNBC after months of intense takeover speculation. “Thanks to the cash we raised… We are in a position to have cash until the end of 2029, and…
A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. As new GLP-1 drugs enter the U.S. market and landmark Medicare coverage rolls out, one thing remains the same: Most employers still aren’t covering those drugs for…
Millions of older Americans in Medicare are about to receive a benefit that has never existed before: coverage of obesity drugs. Starting Wednesday, eligible beneficiaries can get GLP-1s to treat obesity for a copay of just $50 per month. It’s a watershed move that could unlock a vast new patient population for Novo Nordisk and…
Shares of French biotech company Abivax soared Tuesday after it released fresh data on its lead drug for bowel disease, clawing back heavy losses from earlier in the month when the same trial had investors questioning the drug’s future. Abivax stock was last trading up 34% at 111.7 euros. The move comes after it crashed…
Eli Lilly and Regeneron are among the first seven companies the U.S. Food and Drug Administration selected for a pilot program designed to accelerate reviews of new domestic pharmaceutical manufacturing facilities, CNBC has learned. Lilly, Regeneron, Amneal, Cellares, Fujifilm Biotechnologies, Kriya Therapeutics and Kyowa Kirin are the first companies that will participate in the FDA’s…
